Detalhe da pesquisa
1.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
N Engl J Med
; 389(26): 2436-2445, 2023 Dec 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37921461
2.
Protein N-glycans in Healthy and Sclerotic Glomeruli in Diabetic Kidney Disease.
J Am Soc Nephrol
; 2024 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38771634
3.
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Kidney Int
; 105(1): 189-199, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37914086
4.
Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis.
Kidney Int
; 105(3): 447-449, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38388147
5.
Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis.
Kidney Int
; 105(1): 31-34, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38182299
6.
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lancet
; 402(10405): 859-870, 2023 09 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37591292
7.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Lancet
; 401(10388): 1584-1594, 2023 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37015244
8.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Lancet
; 402(10417): 2077-2090, 2023 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37931634
9.
IgA nephropathy: the lectin pathway and implications for targeted therapy.
Kidney Int
; 104(2): 254-264, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37263354
10.
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Kidney Int
; 103(2): 391-402, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36270561
11.
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
N Engl J Med
; 383(12): 1117-1128, 2020 09 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32937045
12.
Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial.
Nephrol Dial Transplant
; 38(12): 2733-2742, 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37463054
13.
The lupus nephritis management renaissance.
Kidney Int
; 101(2): 242-255, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34619230
14.
The cell membrane repair protein MG53 modulates transcription factor NF-κB signaling to control kidney fibrosis.
Kidney Int
; 101(1): 119-130, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34757120
15.
Prediction models of treatment response in lupus nephritis.
Kidney Int
; 101(2): 379-389, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34871620
16.
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
Kidney Int
; 101(2): 403-413, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34560137
17.
Molecular profiling of kidney compartments from serial biopsies differentiate treatment responders from non-responders in lupus nephritis.
Kidney Int
; 102(4): 845-865, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35788359
18.
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Lancet
; 397(10289): 2070-2080, 2021 05 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33971155
19.
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
N Engl J Med
; 381(1): 36-46, 2019 07 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31269364
20.
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.
Ann Rheum Dis
; 81(1): 100-107, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34615636